A report published by Fior Markets states that the global antibiotic resistance market could reach USD 13.16 Billion by 2025 from USD 8.21 Billion in 2017. The market is expected to obtain a CAGR of 6.20% during the forecast period from 2018-2025. Antibiotic resistance market experienced high growth in North America. The factors contributed to the growth of this market include the presence of ample opportunities for manufacturers, acquisition of smaller entrants by large pharmaceutical companies with novel antibiotics, the launch of numerous drugs and the use of novel therapies.
Global Antibiotic Resistance Market by Disease (Complicated Urinary Tract Infection, Complicated Intra-Abdominal Infections, Blood Stream Infections, Clostridium difficile infections others), Pathogen, Drug Class, Region” and Global Forecast 2018-2025.
DOWNLOAD FREE SAMPLE REPORT:https://www.fiormarkets.com/report-detail/362194/request-sample
Crucial players operating in the market include Pfizer, Merck, Allergan, and Melinta Therapeutics., Novartis AG, GlaxoSmithKline PLC, Merck & Co. Inc, Pfizer Inc, Novartis AG, Sanofi SA, Johnson & Johnson, Shionogi, Lupin, Sun Pharma, Teva, Mylan among others. Biotech companies such as Achaogen and Nabriva Therapeutics are the main dominant of antibiotic resistance market and shaping the future of the market. Major pharmaceutical companies are purchasing small manufacturers. For example, Pfizer acquired Astra Zeneca’s marketed drugs, Zavicefta and Zinforo, and late-stage antibiotics. This led to the expansion of the company’s portfolio of antibiotics. In 2018, AmpliPhi Biosciences Corporation presented a poster of a successful case study of AB-PA01 bacteriophage therapy on a patient with cystic fibrosis.
The disease segment is divided into cUTI, cIAI, BSI, CDI, ABSSSI, HABP/VABP, and CABP. In 2017, the cUTI segment held USD 1.06 Billion and it is now dominating the antibiotic resistance market. Key growth contributors include Owing to the treatment cost and limited treatment alternatives for Gram-negative pathogens, which account for the majority of infection cases. In 2017, ESBL-producing held the largest share in pathogen segment. Other growth drivers of the segment include high resistance to current treatment alternatives and shifting towards novel antibiotics. Drug class segment is sub-segmented into oxazolidinones, lipoglycopeptides, tetracyclines, cephalosporins, combination therapies, and others. The high demand for these drugs from developing countries is highly contributing to the market growth.
Additional factors driving the market are the emergence of multi-drug resistant pathogens and a high burden of antibiotic-resistant infections. Several biotech companies are developing therapies for antibiotic resistance which is also a growth fuelling factor of this market. Fewer profit margins for marketed drugs and lower return on investments are predicted to inhibit the growth of the market. However, in developed markets, funding from international organizations serves as a catalyst.
Customization of the Report:
This report can be customized to meet the client’s requirements. Please connect with our sales team (firstname.lastname@example.org), who will ensure that you get a report that suits your needs.